Solace Pharma Closes Boston-Area Office After Pain Treatment Fails in Clinical Trial

Polaris Venture Partners, and InterWest Partners of Menlo Park, CA and Dallas. Solace is still working closely with Woolf and the firm’s other founders here, the CEO says. The firm’s Boston-area board members include Daphne Zohar, founder and managing director of PureTech, and Kevin Bitterman, a principal at Polaris.

“We’re an international company,” Forster says, “but our heart and soul remains in Boston.”

The firm has no other products in clinical trials, Forster says, but it has backup programs with molecules that are showing promise in pre-clinical studies, he says. The company is considering options to advance its remaining experimental pain treatments, including raising more venture capital and forming a corporate partnership.

A big plus for Solace is the need for more effective pain treatments. One opportunity in this multibillion-dollar market is the push to find alternatives to opioid painkillers, which sometimes don’t work and can lead to serious addictions and decreased respiratory function.

Meantime, Forster is embracing a highly virtual business model for the startup. He says that the firm is able to operate with a lean staff because it works with 46 consultants who operate all over the globe. In his previous job as head of European development for New York-based drug giant Pfizer (NYSE:[[ticker:PFE]]), Forster says, he grew comfortable with this model after evaluating the use of outside consultants and contract research organizations (CROs) to provide services from chemistry research to sales and other duties. (Last week I wrote about why virtual business models make sense for some biotech firms.)

“When I left [Pfizer],” Forster says, “my assessment of the business was that there would be sufficient quality, if it was managed properly, in CROs and through consultants and individuals, who are willing to work on a part-time basis, to run a company.”

Last week Forster was in Boston for a Solace board meeting, and he plans to continue to travel back and forth between England and Boston on a regular basis for company business. And it appears that while the company no longer has a physical presence in Boston, its virtual network of founders, investors, and consultants here is very much intact.

Author: Ryan McBride

Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News. Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.